Dyslipidemia Therapeutics Market
Dyslipidemia Therapeutics Market Study by Low-density Lipoproteins (LDL) and Triglycerides for Hospital Pharmacies, Drug Stores, and Retail Stores from 2023 to 2033
Analysis of Dyslipidemia Therapeutics Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Dyslipidemia Therapeutics Market Outlook (2023 to 2033)
The global dyslipidemia therapeutics market is valued at US$ 41.55 billion in 2023 and is forecasted to exhibit expansion at a CAGR of 2.5% over the next ten years. This Fact.MR market study predicts global demand for dyslipidemia therapeutics to accumulate a market revenue of US$ 53.2 billion by the end of 2033.
Cholesterol plays a crucial role in the health of an individual and an imbalance of low-density lipoprotein cholesterol, (LDL-C), high-density lipoprotein (HDL), and triglycerides cause dyslipidemia, which further leads to the development of cardiovascular disorders.
Improper eating habits, adoption of a sedentary lifestyle, and lack of physical activity are key prospects that are anticipated to foster demand for dyslipidemia therapeutics in the future. High consumption of alcohol and tobacco is also anticipated to increase the risk of dyslipidemia and boost dyslipidemia drug sales throughout the forecast period.
Supportive government initiatives to boost awareness regarding dyslipidemia and surging investments in medical research are other key aspects that could further bolster dyslipidemia therapeutics demand over the next ten years. The expanding aging population around the world is also anticipated to be a key prospect that could influentially alter the consumption of dyslipidemia therapeutics throughout the forecast period and beyond.
Dyslipidemia has been associated with an increased risk of ischemic heart diseases that are witnessing a notable hike in incidence in recent years and have been known to claim many lives around the world as well.
- As per a study published on the National Institutes of Health website, nearly 1.72% population of the world is affected by ischemic heart diseases with Eastern European countries expected to lead in terms of prevalence in the future.
On the flip side, lack of awareness regarding dyslipidemia and the presence of stringent regulatory mandates for new drug approvals around the world are anticipated to constrain dyslipidemia therapeutics consumption trends in the long run. The high initial cost of development and research for dyslipidemia therapeutics formulation is also projected to obstruct market growth to a certain extent. However, increasing healthcare expenditure around the world is also predicted to create an opportune business scope for dyslipidemia therapeutics vendors going forward.
An elaborative assessment of local supply, product standards, safety regulations, and other influential aspects has been discussed extensively in this recently updated dyslipidemia therapeutics market research study by Fact.MR, a market research and competitive intelligence provider.
| Report Attributes | Details |
|---|---|
| Dyslipidemia Therapeutics Market Size (2023) | US$ 41.55 Billion |
| Projected Market Value (2033F) | US$ 53.2 Billion |
| Global Market Growth Rate (2023 to 2033) | 2.5% CAGR |
| Authoritative Regional Market | North America |
| Key Companies Profiled | Mylan; AstraZeneca; Novartis AG; Abbot Laboratories; Amgen; Kowa Pharmaceuticals America Inc.; Sanofi; Novelion Therapeutics; Merck & Co.; Pfizer |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What Role Will New Companies Play in Determining the Future of Dyslipidemia Therapeutics?
“Development of Novel Cholesterol-lowering Solutions”
Aspiring dyslipidemia therapeutics providers are anticipated to focus on research and development of novel dyslipidemia drugs and medications that reduce cholesterol. Start-ups are approaching dyslipidemia from unique angles while developing products that not only help in the treatment of dyslipidemia but could also be able to prevent it from developing in people.
- In September 2021, researchers from a Brazilian start-up called Crop Biotecnologia, revealed that they had developed a new platform to express peptides in tomatoes to use them in dyslipidemia treatment and other chronic disease treatments. The peptide can reduce bad cholesterol (LDL) levels by inhibiting the PCSK9 protein that breaks down LDL receptors.
- 89Bio Inc., a biotechnology company founded in 2018, is also focusing on the development of its new drug called pegozafermin, which could address the need for efficacious therapies for hypertriglyceridemia and revolutionize the global dyslipidemia marketplace in the future.
New dyslipidemia therapeutics manufacturers are also focusing on raising new capital to fund their business expansion efforts and channel more investments in their R&D sector.
- In September 2020, Gruthan Bioscience LLC, a start-up founded by a researcher at the Medical University of South Carolina, was awarded a Small Business Transfer (STTR) award from the National, Heart, Blood, and Lung Institute. The new company was expected to develop novel cholesterol-lowering drugs.
An elaborative account of the current and forecasted start-up scenario on a global and regional level has been exclusively discussed in this latest dyslipidemia therapeutics research study by skilled analysts at Fact.MR.
Country-wise Insights
Why Should Dyslipidemia Therapeutics Suppliers Target the United States?
“High Prevalence of Obesity in the Country”
Obesity has become a major public health issue for the population of the United States and this is projected to be a prime factor that is estimated to benefit dyslipidemia therapeutics shipments across the forecast period. Moreover, the presence of developed healthcare infrastructure and key pharmaceutical manufacturing companies are also expected to favor market development over the next ten years.
Increasing investments in medical R&D, a growing geriatric population, rising cases of cardiovascular disorders, and surging consumption of nutraceuticals in the country are other key aspects that could augment the consumption of dyslipidemia medication in the future. Surging cases of diabetes are also expected to create an opportune market scenario for dyslipidemia therapeutics companies and provide lucrative business scope going forward.
Will Japan Be an Investment-worthy Space for Dyslipidemia Therapeutic Providers?
“Rapidly Expanding Senescent Population Propelling Dyslipidemia Therapeutics Demand”
The healthcare industry of Japan is largely driven by its increasing aging population, which is estimated to account for more than 1/3 of its total population at present. Elder people are more at risk of being affected by cardiovascular disorders and this is a key factor that could provide highly lucrative opportunities for dyslipidemia therapeutics companies in the future.
Increasing investments in healthcare infrastructure development in the country are also expected to fuel sales of heart failure therapeutics and HDL therapeutics across the forecast period and beyond. However, low obesity and less consumption of saturated fats in Japan as compared to countries such as the United States contribute to a lower incidence of cardiovascular diseases, which could temporarily prove to be a disadvantage for dyslipidemia therapeutics suppliers in the country.
Changing dietary preferences, the increasing influence of Western culture, and steadily increasing obesity coupled with a rising number of elder people are expected to create highly remunerative business opportunities by the end of the forecast period.
What Prospects are Driving Demand for Dyslipidemia Therapeutics in Europe?
“High Incidence of Cardiovascular Diseases and Increasing Approval of Novel Therapeutics”
European countries have been witnessing a notable hike in the incidence of cardiovascular disorders and this is anticipated to significantly boost demand for dyslipidemia therapeutics over the coming years. The high prevalence of chronic disorders, the increasing number of people being affected by obesity and diabetes, growing aging population, and increasing healthcare expenditure are other key aspects that are common for dyslipidemia therapeutics demand in almost all European countries.
Increasing number of approvals for novel dyslipidemia drugs in European countries and the growing availability of novel dyslipidemia therapeutics are also expected to crucial augment sales growth over the next ten years. Germany and Russia are anticipated to provide highly lucrative business opportunities for dyslipidemia therapeutics suppliers in the future.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Category-wise Insights
Which Channel Leads Dyslipidemia Therapeutics Sales?
“Hospital Pharmacies Accounting for Authoritative Market Share”
Based on distribution channel, the dyslipidemia therapeutics market is segmented into hospital pharmacies, drug stores, retail stores, and mail order pharmacies.
The surging rate of hospitalization and an increasing number of dyslipidemia treatments being performed in hospital settings are projected to bolster sales of dyslipidemia therapeutics from hospital pharmacies over the coming years. The growing availability of novel treatments in hospitals is also a key factor promoting dyslipidemia drug sales through hospital pharmacies across the forecast period.
Sales of dyslipidemia therapeutics through mail order pharmacies are anticipated to have a bright outlook in the future owing to increasing medical tourism and growing demand for novel treatment procedures around the world.
Competitive Landscape
Prime dyslipidemia therapeutics companies are focusing on launching new products and expanding their business scope around the world. Dyslipidemia drug providers are also hastening the launch of these novel drugs by filing for approval with regulatory authorities and trying to gain a competitive advantage by getting approved before their competitors.
- In May 2022, Zydus Lifesciences Limited, an Indian pharmaceutical manufacturing company, announced the regulatory filing of its new drug called Bemdac which was expected to be used for the treatment of patients affected with uncontrolled LDL-cholesterol (LDL-c). The product on approval was expected to be a crucial addition to Zydus’s dyslipidemia and cardiovascular medication portfolio.
Additional information about new developments by top dyslipidemia therapeutics producers such as Merck & Co., Mylan, AstraZeneca, Novartis AG, Pfizer, etc., and how they influence aspects such as product standards and pricing trends have been examined closely in this revised Fact.MR research analysis.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Key Segments of Dyslipidemia Therapeutics Industry Research
-
By Type :
- Low-density Lipoproteins (LDL)
- Triglycerides
-
By Drug Class :
- Statins
- Non-Statins
- PCSK9 Inhibitors
- Cholesterol Absorption Inhibitors
- Bile Acid Resins
- Fibrate
- Others
- Combination Drugs
-
By Distribution Channel :
- Hospital Pharmacies
- Drug Stores
- Retail Stores
- Mail Order Pharmacies
-
By Region :
- North America
- Latin America
- Europe
- APAC
- MEA
Table of Content
- 1. Executive Summary
- 2. Market Introduction
- 3. Market Dynamics
- 4. Global Market Analysis and Forecast
- 4.1. Global Market Analysis by Type
- 4.1.1. Low-density Lipoproteins (LDL)
- 4.1.2. Triglycerides
- 4.2. Market Analysis by Drug Class
- 4.2.1. Statins
- 4.2.2. Non-Statins
- 4.2.2.1. PCSK9 inhibitors
- 4.2.2.2. Cholesterol absorption inhibitors
- 4.2.2.3. Bile Acid resins
- 4.2.2.4. Fibrate
- 4.2.2.5. Others
- 4.2.3. Combination Drugs
- 4.3. Market Analysis by Distribution Channel
- 4.3.1. Hospitals Pharmacies
- 4.3.2. Drug Stores
- 4.3.3. Retail Stores
- 4.3.4. Mail Order Pharmacies
- 4.1. Global Market Analysis by Type
- 5. North America Market Analysis
- 6. Latin America Market Analysis
- 7. Europe Market Analysis
- 8. CIS & Russia Market Analysis
- 9. Asia Pacific Excluding Japan & China Market Analysis
- 10. China Market Analysis
- 11. Japan Market Analysis
- 12. MEA Market Analysis
- 13. Competitive Assessment
- 14. Company Profiles
- 14.1. AstraZeneca
- 14.2. Kowa Pharmaceuticals America, Inc.
- 14.3. Merck & Co.
- 14.4. Pfizer
- 14.5. Sanofi
- 14.6. Amgen
- 14.7. Novelion Therapeutics
- 14.8. Mylan
- 14.9. Abbott Laboratories
- 14.10. Novartis AG
- 15. Assumptions and Acronyms Used
- 16. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
Table 2: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
Table 3: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 4: Global Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 5: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
Table 6: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
Table 7: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 8: North America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 9: Latin America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
Table 10: Latin America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
Table 11: Latin America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 12: Latin America Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 13: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
Table 14: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
Table 15: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 16: Europe Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 17: CIS & Russia Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
Table 18: CIS & Russia Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 19: CIS & Russia Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 20: Asia-Pacific ex. Japan & China Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
Table 21: Asia-Pacific ex. Japan & China Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
Table 22: Asia-Pacific ex. Japan & China Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 23: Asia-Pacific ex. Japan & China Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 24: Japan Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
Table 25: Japan Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 26: Japan Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 27: China Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
Table 28: China Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 29: China Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
Table 30: MEA Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
Table 31: MEA Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
Table 32: MEA Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
Table 33: MEA Market Size (US$ Mn) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Market Value Share 2023E, By Region
Figure 2: Global Market Value Share, By Type
Figure 3: Global Market Size (US$ Mn) Analysis, 2018 to 2022
Figure 4: Global Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033
Figure 5: Global Market Attractiveness Analysis, By Region
Figure 6: Global Market Value Share Analysis, By Region, 2022 & 2033, By Region
Figure 7: Global Market Size (US$ Mn) Analysis, 2018 to 2022, By Low-density Lipoproteins (LDL)
Figure 8: Global Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033, By Low-density Lipoproteins (LDL)
Figure 9: Global Market Size (US$ Mn) Analysis, 2018 to 2022, By Triglycerides
Figure 10: Global Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033, By Triglycerides
Figure 11: Global Market Attractiveness Analysis, By Type
Figure 12: Global Market Value Share Analysis, By Region, 2022 & 2033, By Type
Figure 13: Global Market Size (US$ Mn) Analysis, 2018 to 2022, By Statins
Figure 14: Global Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033, By Statins
Figure 15: Global Market Size (US$ Mn) Analysis, 2018 to 2022, By Non-Statins
Figure 16: Global Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033, By Non-Statins
Figure 17: Global Market Size (US$ Mn) Analysis, 2018 to 2022, By Combinations Drugs
Figure 18: Global Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033, By Combinations Drugs
Figure 19: Global Market Attractiveness Analysis, By Drug Class
Figure 20: Global Market Value Share Analysis, By Region, 2022 & 2033, By Drug Class
Figure 21: Global Market Size (US$ Mn) Analysis, 2018 to 2022, By Hospitals Pharmacies
Figure 22: Global Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033, By Hospitals Pharmacies
Figure 23: Global Market Size (US$ Mn) Analysis, 2018 to 2022, By Drug Stores
Figure 24: Global Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033, By Drug Stores
Figure 25: Global Market Size (US$ Mn) Analysis, 2018 to 2022, By Retail Stores
Figure 26: Global Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033, By Retail Stores
Figure 27: Global Market Size (US$ Mn) Analysis, 2018 to 2022, By Mail Order Pharmacies
Figure 28: Global Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033, By Mail Order Pharmacies
Figure 29: Global Market Attractiveness Analysis, By Distribution Channel
Figure 30: Global Market Value Share Analysis, By Region, 2022 & 2033, By Distribution Channel
Figure 31: North America Market, Snapshot
Figure 32: North America Market Size (US$ Mn) Analysis, 2018 to 2022
Figure 33: North America Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033
Figure 34: North America Market Value Share, by Country Type (2022A)
Figure 35: North America Market Value Share, by Type (2022A)
Figure 36: North America Market Value Share, by Drug Class (2022A)
Figure 37: North America Market Value Share, by Distribution Channel (2022A)
Figure 38: North America Market Attractiveness Analysis, By Country
Figure 39: North America Market Value Share Analysis, By Region, 2022 & 2033, By Country
Figure 40: North America Market Attractiveness Analysis, By Type
Figure 41: North America Market Value Share Analysis, By Region, 2022 & 2033, By Type
Figure 42: North America Market Attractiveness Analysis, By Drug Class
Figure 43: North America Market Value Share Analysis, By Region, 2022 & 2033, By Drug Class
Figure 44: North America Market Attractiveness Analysis, By Distribution Channel
Figure 45: North America Market Value Share Analysis, By Region, 2022 & 2033, By Distribution Channel
Figure 46: Latin America Market, Snapshot
Figure 47: Latin America Market Size (US$ Mn) Analysis, 2018 to 2022
Figure 48: Latin America Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033
Figure 49: Latin America Market Value Share, by Country Type (2022A)
Figure 50: Latin America Market Value Share, by Type (2022A)
Figure 51: Latin America Market Value Share, by Drug Class (2022A)
Figure 52: Latin America Market Value Share, by Distribution Channel (2022A)
Figure 53: Latin America Market Attractiveness Analysis, By Country
Figure 54: Latin America Market Value Share Analysis, By Region, 2022 & 2033, By Country
Figure 55: Latin America Market Attractiveness Analysis, By Type
Figure 56: Latin America Market Value Share Analysis, By Region, 2022 & 2033, By Type
Figure 57: Latin America Market Attractiveness Analysis, By Drug Class
Figure 58: Latin America Market Value Share Analysis, By Region, 2022 & 2033, By Drug Class
Figure 59: Latin America Market Attractiveness Analysis, By Distribution Channel
Figure 60: Latin America Market Value Share Analysis, By Region, 2022 & 2033, By Distribution Channel
Figure 61: Europe Market, Snapshot
Figure 62: Europe Market Size (US$ Mn) Analysis, 2018 to 2022
Figure 63: Europe Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033
Figure 64: Europe Market Value Share, by Country Type (2022A)
Figure 65: Europe Market Value Share, by Type (2022A)
Figure 66: Europe Market Value Share, by Drug Class (2022A)
Figure 67: Europe Market Value Share, by Distribution Channel (2022A)
Figure 68: Europe Market Attractiveness Analysis, By Country
Figure 69: Europe Market Value Share Analysis, By Region, 2022 & 2033, By Country
Figure 70: Europe Market Attractiveness Analysis, By Type
Figure 71: Europe Market Value Share Analysis, By Region, 2022 & 2033, By Type
Figure 72: Europe Market Attractiveness Analysis, By Drug Class
Figure 73: Europe Market Value Share Analysis, By Region, 2022 & 2033, By Drug Class
Figure 74: Europe Market Attractiveness Analysis, By Distribution Channel
Figure 75: Europe Market Value Share Analysis, By Region, 2022 & 2033, By Distribution Channel
Figure 76: CIS & Russia Market, Snapshot
Figure 77: CIS & Russia Market Size (US$ Mn) Analysis, 2018 to 2022
Figure 78: CIS & Russia Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033
Figure 79: CIS & Russia Market Value Share, by Type (2022A)
Figure 80: CIS & Russia Market Value Share, by Drug Class (2022A)
Figure 81: CIS & Russia Market Value Share, by Distribution Channel (2022A)
Figure 82: CIS & Russia Market Attractiveness Analysis, By Type
Figure 83: CIS & Russia Market Value Share Analysis, By Region, 2022 & 2033, By Type
Figure 84: CIS & Russia Market Attractiveness Analysis, By Drug Class
Figure 85: CIS & Russia Market Value Share Analysis, By Region, 2022 & 2033, By Drug Class
Figure 86: CIS & Russia Market Attractiveness Analysis, By Distribution Channel
Figure 87: CIS & Russia Market Value Share Analysis, By Region, 2022 & 2033, By Distribution Channel
Figure 88: Asia-Pacific ex. Japan & China Market, Snapshot
Figure 89: Asia-Pacific ex. Japan & China Market Size (US$ Mn) Analysis, 2018 to 2022
Figure 90: Asia-Pacific ex. Japan & China Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033
Figure 91: Asia-Pacific ex. Japan & China Market Value Share, by Country Type (2022A)
Figure 92: Asia-Pacific ex. Japan & China Market Value Share, by Type (2022A)
Figure 93: Asia-Pacific ex. Japan & China Market Value Share, by Drug Class (2022A)
Figure 94: Asia-Pacific ex. Japan & China Market Value Share, by Distribution Channel (2022A)
Figure 95: Asia-Pacific ex. Japan & China Market Attractiveness Analysis, By Country
Figure 96: Asia-Pacific ex. Japan & China Market Value Share Analysis, By Region, 2022 & 2033, By Country
Figure 97: Asia-Pacific ex. Japan & China Market Attractiveness Analysis, By Type
Figure 98: Asia-Pacific ex. Japan & China Market Value Share Analysis, By Region, 2022 & 2033, By Type
Figure 99: Asia-Pacific ex. Japan & China Market Attractiveness Analysis, By Drug Class
Figure 100: Asia-Pacific ex. Japan & China Market Value Share Analysis, By Region, 2022 & 2033, By Drug Class
Figure 101: Asia-Pacific ex. Japan & China Market Attractiveness Analysis, By Distribution Channel
Figure 102: Asia-Pacific ex. Japan & China Market Value Share Analysis, By Region, 2022 & 2033, By Distribution Channel
Figure 103: Japan Market, Snapshot
Figure 104: Japan Market Size (US$ Mn) Analysis, 2018 to 2022
Figure 105: Japan Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033
Figure 106: Japan Market Value Share, by Type (2022A)
Figure 107: Japan Market Value Share, by Drug Class (2022A)
Figure 108: Japan Market Value Share, by Distribution Channel (2022A)
Figure 109: Japan Market Attractiveness Analysis, By Type
Figure 110: Japan Market Value Share Analysis, By Region, 2022 & 2033, By Type
Figure 111: Japan Market Attractiveness Analysis, By Drug Class
Figure 112: Japan Market Value Share Analysis, By Region, 2022 & 2033, By Drug Class
Figure 113: Japan Market Attractiveness Analysis, By Distribution Channel
Figure 114: Japan Market Value Share Analysis, By Region, 2022 & 2033, By Distribution Channel
Figure 115: China Market, Snapshot
Figure 116: China Market Size (US$ Mn) Analysis, 2018 to 2022
Figure 117: China Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033
Figure 118: China Market Value Share, by Type (2022A)
Figure 119: China Market Value Share, by Drug Class (2022A)
Figure 120: China Market Value Share, by Distribution Channel (2022A)
Figure 121: China Market Attractiveness Analysis, By Type
Figure 122: China Market Value Share Analysis, By Region, 2022 & 2033, By Type
Figure 123: China Market Attractiveness Analysis, By Drug Class
Figure 124: China Market Value Share Analysis, By Region, 2022 & 2033, By Drug Class
Figure 125: China Market Attractiveness Analysis, By Distribution Channel
Figure 126: China Market Value Share Analysis, By Region, 2022 & 2033, By Distribution Channel
Figure 127: MEA Market, Snapshot
Figure 128: MEA Market Size (US$ Mn) Analysis, 2018 to 2022
Figure 129: MEA Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2023 to 2033
Figure 130: MEA Market Value Share, by Country Type (2022A)
Figure 131: MEA Market Value Share, by Type (2022A)
Figure 132: MEA Market Value Share, by Drug Class (2022A)
Figure 133: MEA Market Value Share, by Distribution Channel (2022A)
Figure 134: MEA Market Attractiveness Analysis, By Country
Figure 135: MEA Market Value Share Analysis, By Region, 2022 & 2033, By Country
Figure 136: MEA Market Attractiveness Analysis, By Type
Figure 137: MEA Market Value Share Analysis, By Region, 2022 & 2033, By Type
Figure 138: MEA Market Attractiveness Analysis, By Drug Class
Figure 139: MEA Market Value Share Analysis, By Region, 2022 & 2033, By Drug Class
Figure 140: MEA Market Attractiveness Analysis, By Distribution Channel
Figure 141: MEA Market Value Share Analysis, By Region, 2022 & 2033, By Distribution Channel
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the dyslipidemia therapeutics market?
The global dyslipidemia therapeutics market stands at US$ 41.55 billion in 2023.
What is the estimated market size for dyslipidemia therapeutics by 2033?
Dyslipidemia therapeutics demand is set to rake in revenue worth US$ 53.2 billion by the end of 2033.
What is the predicted growth rate of the dyslipidemia therapeutics market?
Over the next ten years, worldwide revenue from dyslipidemia therapeutics is expected to rise at 2.5% CAGR.
Which regional market dominates the global landscape?
Demand for dyslipidemia therapeutics in North America accounts for a commanding share of the global market at present.
Who are the key dyslipidemia therapeutics companies?
AstraZeneca, Novartis AG, Abbot Laboratories, Amgen, and Kowa Pharmaceuticals America Inc. are leading dyslipidemia therapeutics suppliers.
Dyslipidemia Therapeutics Market